- The trend backdrop is active with a 37-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.
GNFT
PAR
Week ended 07 Aug 2026
Weekly Investor Report
Genfit S.A. · Healthcare · Biotechnology
Latest close
13.66 EUR
-7.7%
latest week
Weekly setup
Mixed setup
The weekly trend is active. Price is 47.4% above the Trend Line and sits at 85.4% of its 52-week range. The latest completed week returned -7.7%, after a -0.6% four-week move. The latest news-sentiment score is 50/100.
Setup score
71
out of 100
Latest Close
13.66 EUR
7 Aug 2026
1W Return
-7.7%
latest completed week
4W Return
-0.6%
short-term follow-through
12W Return
58.8%
quarterly tape
Trend Breadth
82.7%
43 of 52 weeks active
Volume Ratio
1.3x
vs 13-week average
- 7 reversal markers appear in the recent smart-money tape.
- The latest week was a sharp negative move.
- Latest weekly return ranks in the weaker part of its sector group.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-7.7%
Latest completed week; four-week move -0.6%.
Indicator stack
90/80
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
50/100
6 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is active. Price is 47.4% above the Trend Line and sits at 85.4% of its 52-week range. The latest completed week returned -7.7%, after a -0.6% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 1.3x the 13-week average. Participation is around or above normal and provides reasonable confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.9412-week average 0.86
12-week confirmation
Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure6/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.94Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers77 reversal markers
No recent accumulation markers. 7 reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -0.6% over four weeks, 58.8% over 12 weeks, and 310.2% over one year. The current trend has remained active for 37 consecutive weeks.
Performance by holding period
Active trend streak37 weeks
Active weeks in one year43
Trend breadth82.7%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure1.36Latest activity-pressure read.
Pressure change72.6%Four-week change in activity pressure.
Leadership82.23Latest relative-leadership reading.
RS change-27.9%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
A published fundamentals and factor snapshot is not available for this company.
No published fundamental snapshot is available for this company.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment50/100
Weighted news tone is neutral across 6 relevant articles.
0 positive · 6 neutral · 0 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-11.8%Distance below the 52-week high.
13-week volatility9.1%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher16 of 2610 weeks finished lower.
Best week+27.4%Week of 3 Jul.
Worst week-10.9%Week of 24 Apr.
Latest week-7.7%Week of 7 Aug.
Shape of recent returns
Strong gains11
Modest gains5
Flat weeks0
Modest losses4
Sharp losses6
Recent vol9.1%13-week weekly-return volatility.
Base vol7.6%52-week weekly-return volatility.
Up/down split33/19Count of positive and negative weeks in the 52-week window.
Average skew7.1% / -4.1%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorFR Healthcare
4-week rank40 / 76
Group average0.7%
Trend breadth26.3%
Trend26.3%active weekly trend signals
MD40.8%positive activity pressure
RS19.7%positive relative leadership
Four-week leaders
IndustryFR Biotechnology
4-week rank19 / 33
Group average4.5%
Trend breadth27.3%
Trend27.3%active weekly trend signals
MD36.4%positive activity pressure
RS21.2%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape70/100
Trend, activity pressure, participation, and risk combine to a 70/100 tape read.
Indicator analysis72/100Latest 12-week confirmation: trend 12/12, activity pressure 6/12, relative leadership 12/12.
Activity pressure 0.94; 7 reversal markers Factors50/100No published factor snapshot is available yet.
Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment50/100Weighted news tone is neutral across 6 relevant articles.
Genfit SA Revenue Breakdown – SWB:XUP Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 13.66 EUR | -7.7% | 9.27 EUR | 4.77 EUR | 1.36 | 82.23 | 1.6M | On |
| 31 Jul 2026 | 14.80 EUR | 10.1% | 8.99 EUR | 4.71 EUR | 1.48 | 107.48 | 2.2M | On |
| 24 Jul 2026 | 13.44 EUR | 4.2% | 8.67 EUR | 4.64 EUR | 1.43 | 97.36 | 1.7M | On |
| 17 Jul 2026 | 12.90 EUR | -6.1% | 8.40 EUR | 4.57 EUR | 1.08 | 95.51 | 1.8M | On |
| 10 Jul 2026 | 13.74 EUR | 6.2% | 8.13 EUR | 4.51 EUR | 0.79 | 114.03 | 2.7M | On |
| 3 Jul 2026 | 12.94 EUR | 27.4% | 7.84 EUR | 4.45 EUR | 0.22 | 103.85 | 1.8M | On |
| 26 Jun 2026 | 10.16 EUR | -4.7% | 7.57 EUR | 4.39 EUR | -0.34 | 67.10 | 405.4K | On |
| 19 Jun 2026 | 10.66 EUR | 15.1% | 7.38 EUR | 4.35 EUR | -0.49 | 78.26 | 403.5K | On |
| 12 Jun 2026 | 9.26 EUR | 5.6% | 7.15 EUR | 4.30 EUR | -0.71 | 59.70 | 398.0K | On |
| 5 Jun 2026 | 8.77 EUR | -0.3% | 6.96 EUR | 4.27 EUR | -0.68 | 56.43 | 711.9K | On |
| 29 May 2026 | 8.80 EUR | 3.3% | 6.79 EUR | 4.24 EUR | -0.59 | 60.31 | 920.8K | On |
| 22 May 2026 | 8.52 EUR | -0.9% | 6.61 EUR | 4.21 EUR | -0.54 | 59.04 | 746.1K | On |
| 15 May 2026 | 8.60 EUR | 0.9% | 6.45 EUR | 4.18 EUR | -0.36 | 66.49 | 1.0M | On |
| 8 May 2026 | 8.52 EUR | 5.4% | 6.29 EUR | 4.15 EUR | 0.02 | 64.63 | 770.1K | On |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.